Solutions Through Advanced Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$154,243	21
2024	Research	$300,292	27
2023	Research	$315,909	38
2022	Research	$534,815	48
2021	Research	$648,253	21
2020	Research	$538,411	19
2019	Research	$570,323	11

Breakdown

Who paid Research payments · program years 2019–2025

Novartis Pharmaceuticals Corporation $1,451,473 4 payments
Eli Lilly and Company $1,296,857 80 payments
AbbVie, Inc. $264,799 88 payments
Amgen Inc. $42,159 9 payments
Regeneron Pharmaceuticals, Inc. $3,911 1 payment
Pfizer Inc. $3,018 2 payments
Eli Lilly Export S.A. Puerto Rico Branch $27 1 payment

Studies the money was for Research payments · program years 2019–2025

Pediatric Study in Children With Moderate to Severe Plaque Psoriasis $1,451,473 4 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $184,682 5 payments
A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $132,391 3 payments
A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-To-Severe Atopic Dermatitis $106,219 4 payments
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis $105,369 4 payments
Multicenter, Double-Blind, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-To-Severe Plaque Psoriasis $104,311 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe Or Very Severe Alopecia Areata $103,527 10 payments
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata $99,098 2 payments
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $97,468 8 payments
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 $86,387 35 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.